Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association (EHA) Hybrid Congress being held June 13-16, 2024, in Madrid, Spain, and via livestream.

Clinical data from patients treated in the Phase 1/2/3 RUBY trial of reni-cel in patients with severe sickle cell disease and in the Phase 1/2 EdiTHAL trial of reni-cel in patients with transfusion-dependent beta thalassemia will be shared, including:

• RUBY trial, Abstract #S285, oral presentation on Saturday, June 15:
  • Clinical data on at least 18 patients, with 2-21 months follow-up.
  • Efficacy data, including total hemoglobin, fetal hemoglobin, and vaso-occlusive events (VOEs).
  • Safety data, including neutrophil and platelet engraftment.

• EdiTHAL trial, Abstract #P1476, poster presentation on Friday, June 14:
  • Clinical data on seven patients, with 4-12 months follow-up.
  • Efficacy data, including total hemoglobin, fetal hemoglobin, and transfusion independence.
  • Safety data, including neutrophil and platelet engraftment.

“We are making significant progress with the continued development of reni-cel, and we look forward to sharing clinical data, including longer follow up of the dosed patients from the RUBY and EdiTHAL trials next month at the European Hematology Association Congress. These data further support our belief that reni-cel has the potential to be a clinically differentiated, one-time, durable medicine that can provide life-changing clinical benefits to patients,” said Baisong Mei, M.D., Ph.D., Chief Medical Officer, Editas Medicine. “I would like to thank the participants, their families and caregivers, clinicians, and colleagues at collaborating institutions that contribute to the RUBY and EdiTHAL trials.”

The abstracts can be accessed on the EHA website.

Oral Presentation Details:
Title: Reni-cel, the first AsCas12a gene-edited cell therapy, led to hemoglobin normalization and increased fetal hemoglobin in severe sickle cell disease patients in an interim analysis of the RUBY trial
Presenting Author: Rabi Hanna, M.D., Department of Pediatric Hematology Oncology and Blood and Marrow Transplantation, Cleveland Clinic Children’s, Cleveland, OH, United States